Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder
1996

MRP Gene Expression in Bladder Cancer

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): SC Clifford, DE Neal, J Lunec

Primary Institution: University of Newcastle-upon-Tyne

Hypothesis

The study investigates the expression levels of the MRP gene in high-grade transitional cell carcinoma of the bladder and its implications for chemotherapy resistance.

Conclusion

The study found that MRP mRNA levels are significantly reduced in a greater proportion of high-grade bladder tumors compared to low- and moderate-grade tumors.

Supporting Evidence

  • MRP mRNA levels were significantly reduced in 55% of high-grade tumors compared to only 8% of low-grade tumors.
  • All tumor samples analyzed showed detectable levels of MRP mRNA.
  • MRP mRNA levels varied widely among individual tumors, with a 190-fold range observed.

Takeaway

This study looked at how a gene related to drug resistance behaves in bladder cancer, finding that more advanced tumors often have lower levels of this gene.

Methodology

The study used RT-PCR to quantify MRP mRNA levels in untreated TCC samples and compared them with normal bladder tissue.

Limitations

The study had a limited number of patients and did not find a consistent relationship between MRP levels and chemotherapy response.

Participant Demographics

The study included patients with high-grade transitional cell carcinoma of the bladder, primarily males aged 60-70.

Statistical Information

P-Value

0.018

Statistical Significance

p=0.018

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication